Whats New at V3 - Akcea Therapeutics
Here's a quick look at
what we've been up to...
Akcea, are on a mission to transform the treatment of unaddressed or under-addressed serious and rare diseases with leading-edge, RNA-targeted medicines.
Familial chylomicronemia syndrome (FCS) is a serious and rare lipid disorder characterized by the build-up of chylomicrons (chylomicronemia), a large lipoprotein particle that transport dietary fat and cholesterol in the body. Because chylomicrons are rich in triglycerides, people with FCS have extremely high levels of triglycerides, often reaching 10 to 20 times the normal level. People with FCS cannot break down chylomicrons, so their blood can appear milky in color (lipemic). There are approximately 3,000 to 5,000 patients with FCS worldwide. - Click here to go to their website
The Pop up banner was printed here at V3